Targeted Oncology Staff | Authors


Trending News on Targeted Oncology, Week of January 22, 2021

January 22, 2021

This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.

Lorlatinib Demonstrates Promise for ALK-Rearranged Patients With NSCLC

January 21, 2021

In an interview with Targeted Oncology, Benjamin Solomon, MBBS, PhD, discussed the findings from the CROWN study that compared lorlatinib with crizotinib as treatment of patients with ALK-positive non-small cell lung cancer.

Rationale Taken From Trial Data for Using Daratumumab in Multiple Myeloma

January 19, 2021

During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.